AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18599252
Drug: Recursive partitioning
RxNorm normalized name: Immunoglobulin g1, anti-(human repulsive guidance molecule rgma) (human-mus musculus clone rh116a3 .gamma.1-chain), disulfide with human-mus musculus clone rh116a3 .kappa.-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recursive partitioning (RP) methodology applied to drug treatment retention analysis
Trial: 17697500
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists (GnRHa) plus gonadotrophin therapy with corticosteroids (dexamethasone)
Trial: 17697500
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists (GnRHa) plus gonadotrophin therapy with placebo
Trial: 16138974
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib (0.3 mg)
Trial: 16138974
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib (1.0 mg)
Trial: 16138974
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib (3.0 mg)
Trial: 16138974
Drug: Subconjunctival sham
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival sham injection (Control)
Trial: 9449910
Drug: 0.05% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tazarotene gel administered once or twice daily
Trial: 9449910
Drug: 0.1% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tazarotene gel administered once or twice daily
Trial: 31038476
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification treatment (diet, rehabilitation, education, behavioral therapy) for 12 weeks
Trial: 27748623
Drug: Liposomal amikacin
RxNorm normalized name: amikacin liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal amikacin for inhalation (LAI) 590 mg once daily for 84 days
Trial: 23279373
Drug: Sitagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50 mg/day, increased to 100 mg/day if HbA1c ≥6.5% at 16 weeks)
Trial: 23279373
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg/day, increased to 30 mg/day if HbA1c ≥6.5% at 16 weeks)
Trial: 19786145
Drug: Polypeptide vaccine
RxNorm normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypeptide vaccine (EP-1043)
Trial: 15297403
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC = 5.5 mg/ml x min day 1) and gemcitabine (1000 mg/m(2) days 1 and 8 every 21 days x 3) followed by paclitaxel (225 mg/m(2) every 21 days x 3)
Trial: 15297403
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m(2) day 1), vinorelbine (25 mg/m(2) days 1 and 8 every 21 days x 3) followed by docetaxel (75-100 mg/m(2) every 21 days x 3)
Trial: 11707557
Drug: Very-low-calorie diets
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-calorie diets (VLCDs) with active follow-up treatment including behavior therapy, nutritional education, and exercise
Trial: 7867399
Drug: Selenium supplement
RxNorm normalized name: Selenium supplement
DrugBank: Selenious acid (DB11127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplement (100 micrograms/d for 6-8 weeks)
Trial: 7867399
Drug: Selenium supplement
RxNorm normalized name: Selenium supplement
DrugBank: Selenious acid (DB11127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplement
Trial: 1030548
Drug: Initial and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial and crossover chemotherapy
Trial: 23737390
Drug: Other drug-eluting
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drug-eluting stents (DES)
Trial: 19372620
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg or 40 mg
Trial: 1824048
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitors (MAOI)
Trial: 25888525
Drug: Albendazole (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (three monthly treatments for one year, three consecutive days of supervised drug intake)
Trial: 25888525
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (three monthly treatments for one year, three consecutive days of supervised drug intake)
Trial: 25117425
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a (180 μg/week) + Ribavirin (1000/1200 mg/day)
Trial: 25117425
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2b (1.5 μg/kg/week) + Ribavirin (1000/1200 mg/day)
Trial: 22378331
Drug: Sweet preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweet preload (0.35 L fruit juice)
Trial: 22378331
Drug: Savory preload
RxNorm normalized name: winter savory oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savory preload (0.35 L tomato juice)
Trial: 25885239
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol (1 mg/kg) (n=20)
Trial: 25885239
Drug: Rectal tramadol
RxNorm normalized name: tramadol hydrochloride Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal tramadol (1.5‐2 mg/kg, maximum 100 mg) (n=20)
Trial: 17671253
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly intramuscular injections
Trial: 16225528
Drug: Dicyclomine 20
RxNorm normalized name: dicyclomine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicyclomine 20 mg four times daily
Trial: 12385694
Drug: Ertapenem 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem 1.5 g
Trial: 12385694
Drug: Ertapenem 1
RxNorm normalized name: ertapenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem 1 g and 1.5 g
Trial: 10233270
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine for 1 week
Trial: 10233270
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine for 2 weeks
Trial: 10233270
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine for an additional 4 weeks (for non-responders)
Trial: 10233270
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine for an additional 4 weeks (for Microsporum infections)
Trial: 7479198
Drug: Ascorbate 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbate 4.5 g/day
Trial: 4901340
Drug: Bordetella pertussis
RxNorm normalized name: Bordetella pertussis
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bordetella pertussis vaccine
Trial: 15384292
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block plus labial infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 15384292
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block alone (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Trial: 9648960
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 microg (2x100 microg) via metered dose inhaler with a spacer
Trial: 8024992
Drug: Etodolac 300
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 300 mg twice daily for 4 weeks
Trial: 8024992
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for 4 weeks
Trial: 30531234
Drug: Lofexidine 2.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine 2.16 mg/d
Trial: 30531234
Drug: Lofexidine 2.88
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine 2.88 mg/d
Trial: 20104189
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg alone or in association with 12.5 or 25 mg hydrochlorothiazide (HCTZ)
Trial: 20104189
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg in association with 25 mg HCTZ
Trial: 20104189
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg in association with 25 mg HCTZ
Trial: 20104189
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg in association with 25 mg HCTZ
Trial: 14961168
Drug: Inogatran (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (low molecular weight direct thrombin inhibitor)
Trial: 7907731
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of 1 g of gliadin
Trial: 21679485
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g oligofructose
Trial: 10393452
Drug: Commercial BPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial BPO formulation
Trial: 10393452
Drug: Pharmacopoeial BPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacopoeial BPO formulation
Trial: 6839799
Drug: Choline magnesium
RxNorm normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline magnesium trisalicylate (3 g)
Trial: 6839799
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (2.4 g)
Trial: 31025207
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Fractional CO2 laser + topical tioconazole 28% nail lacquer)
Trial: 31025207
Drug: Topical tioconazole
RxNorm normalized name: tioconazole Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tioconazole 28% nail lacquer
Trial: 30119694
Drug: Personalized chronotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized chronotherapy intervention including individually timed bright light therapy (BLT), bi-weekly tailored physical activity (PA) counseling, and general sleep hygiene education.
Trial: 23095790
Drug: Docetaxel 70
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 70 mg/m² administered intravenously on day 1 of a 3-week cycle
Trial: 19095213
Drug: Telavancin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin (10 mg/kg IV every 24 hours)
Trial: 19095213
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g IV every 12 hours)
Trial: 17947266
Drug: Ophthalmic chloramphenicol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic chloramphenicol (OC)
Trial: 8722072
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (multiple daily injections)
Trial: 8722072
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (continuous subcutaneous insulin infusion)
Trial: 6817944
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sodium cromoglycate (SCG) powder delivered by Spinhaler
Trial: 6817944
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sodium cromoglycate (SCG) delivered by pressurized aerosol
Trial: 28981173
Drug: Oral reflection
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - CORAL REFLECTION (119)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral reflection
Trial: 26667921
Drug: AIT concurrent
RxNorm normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIT concurrent with DIET (E+D, n=12)
Trial: 25136791
Drug: Weekly remote
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly remote monitoring-driven management
Trial: 22392415
Drug: Risperidone plus
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone plus Ginkgo T.D. (80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg)
Trial: 19156094
Drug: Local ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local ozone therapy combined with low-frequency magnetic fields (ozonomagnetophoresis)
Trial: 15665884
Drug: Methadone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (mean 106 mg, range 80-160)
Trial: 15665884
Drug: Buprenorphine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (16 mg sublingual)
Trial: 12773357
Drug: Drug and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug and alcohol use
Trial: 10759236
Drug: Thymosin-alpha1 at
RxNorm normalized name: Thymosin alpha1 (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin-alpha1 at a dose of 900 microg/m2 twice a week for six months
Trial: 10759236
Drug: Thymosin-alpha1 treatment
RxNorm normalized name: Thymosin alpha1 (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin-alpha1 treatment
Trial: 27395385
Drug: 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/day milk-containing LNS
Trial: 27395385
Drug: 20 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g/day milk-containing LNS
Trial: 27395385
Drug: 40 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/day milk-containing LNS
Trial: 27395385
Drug: 20 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g/day milk-free LNS
Trial: 27395385
Drug: 40 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/day milk-free LNS
Trial: 15992652
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg daily, vitamin C 1 g daily, and vitamin E 1,000 U daily
Trial: 12637120
Drug: Glimepiride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1 mg starting dose, titrated to 2 mg and 4 mg)
Trial: 10872928
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 4.0 mg triamcinolone acetonide
Trial: 3897044
Drug: Normal alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal alcohol consumption (336 ml of ethanol per week)
Trial: 3897044
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in alcohol consumption from 350 ml to 70 ml per week
Trial: 27227290
Drug: Teflon infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teflon infusion set in lipohypertrophied tissue
Trial: 27227290
Drug: Teflon infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teflon infusion set in nonlipohypertrophied tissue
Trial: 25027194
Drug: Nebulized fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized fentanyl (4 μg/kg)
Trial: 20403471
Drug: ACEI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI treatment at discharge
Trial: 20403471
Drug: ACEI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI treatment at discharge in patients without heart failure with renal dysfunction
Trial: 15643100
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (SJW) 600-1800 mg for 12 weeks
Trial: 12354174
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 16 weeks
Trial: 9387637
Drug: Placebo medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medicine (control)
Trial: 1561022
Drug: 5.0 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg.kg‐1 caffeine
Trial: 1561022
Drug: 2.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg.kg‐1 caffeine
Trial: 2861907
Drug: Flunarizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (5 mg/day before sleep)
Trial: 28399620
Drug: Linolenic‐glutathione conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linolenic‐glutathione conjugate (Lin‐GSH) cream 2% before UVB irradiation
Trial: 28399620
Drug: Lin‐GSH cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lin‐GSH cream 2% after irradiation
Trial: 28399620
Drug: Naïve arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naïve arm (no treatment)
Trial: 18068523
Drug: Omega-3 FA
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 FA supplementation (1 g eicosapentaenoic acid and 0.7 g docosahexaenoic acid daily)
Trial: 17173824
Drug: Conventional consult
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional consult (CC)
Trial: 9042685
Drug: Special one-year
RxNorm normalized name: segesterone
DrugBank: Segesterone (DB14584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special one-year treatment including polyvitamins, N-acetylcysteine, and therapeutic BAL every 3 months (n = 10)
Trial: 31740092
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (INF) + intramuscular Ketorolac
Trial: 31740092
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (IVF) + intramuscular Ketorolac
Trial: 29654308
Drug: Low-calcium dialysate
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calcium dialysate (LCD, 1.25 mmol/L Ca2+)
Trial: 29654308
Drug: High-calcium dialysate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium dialysate (HCD, 1.5 mmol/L Ca2+)
Trial: 23311688
Drug: Cinnarizine 25
RxNorm normalized name: cinnarizine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 25 mg every 12 hours
Trial: 23311688
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 200 mg every 12 hours
Trial: 17165495
Drug: Pricking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pricking therapy (pricking thyroid gland high point)
Trial: 17165495
Drug: Medication (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (oral administration of tapazole)
Trial: 17165495
Drug: Pricking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pricking therapy
Trial: 11031698
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (specific dosage and duration not mentioned)
Trial: 11031698
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (lower doses than those used for aggressive tocolysis)
Trial: 8282350
Drug: lisinopril (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (5, 10, or 20 mg)
Trial: 8282350
Drug: metoprolol (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (50, 100, or 200 mg)
Trial: 26087670
Drug: Rituximab, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab, 1,000 mg (2 infusions, 14 days apart; repeated at 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Trial: 26087670
Drug: Cyclosporine (CSA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CSA), 3.5‐5 mg/kg/day for 6 months (continued for another 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Trial: 21098626
Drug: mF-G score
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mF-G score greater than six (hirsutism)
Trial: 21098626
Drug: mF-G score
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mF-G score of zero
Trial: 21098626
Drug: Homeostatic model
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeostatic model assessment for insulin resistance